Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | tyrosine kinase | 0.0175 | 0.0146 | 0.0146 |
Trichomonas vaginalis | hypothetical protein | 0.0363 | 0.8925 | 0.5 |
Brugia malayi | Protein kinase domain containing protein | 0.0213 | 0.1923 | 0.1803 |
Schistosoma mansoni | tyrosine kinase | 0.0385 | 1 | 1 |
Schistosoma mansoni | tyrosine kinase | 0.0175 | 0.0146 | 0.0146 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0363 | 0.8925 | 0.5 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0363 | 0.8925 | 0.5 |
Echinococcus granulosus | insulin growth factor 1 receptor beta | 0.0385 | 1 | 1 |
Schistosoma mansoni | tyrosine kinase | 0.0385 | 1 | 1 |
Chlamydia trachomatis | enoyl-acyl-carrier protein reductase | 0.0363 | 0.8925 | 0.5 |
Echinococcus multilocularis | insulin growth factor 1 receptor beta | 0.0385 | 1 | 1 |
Schistosoma mansoni | tyrosine kinase | 0.0175 | 0.0146 | 0.0146 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0363 | 0.8925 | 0.5 |
Echinococcus multilocularis | insulin receptor | 0.0385 | 1 | 1 |
Loa Loa (eye worm) | TK/INSR protein kinase | 0.0385 | 1 | 1 |
Echinococcus granulosus | insulin receptor | 0.0385 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.021 | 0.1777 | 0.1655 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0363 | 0.8925 | 0.5 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0363 | 0.8925 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0363 | 0.8925 | 0.5 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0363 | 0.8925 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.